ACCUNEB (albuterol sulfate) by Teva is clinical pharmacology the prime action of beta-adrenergic drugs is to stimulate adenyl cyclase, the enzyme which catalyzes the formation of cyclic-3',5'-adenosine monophosphate (cyclic amp) from adenosine triphosphate (atp). First approved in 2001.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
ACCUNEB is an inhaled albuterol sulfate solution for nebulizer administration that acts as a beta-2 adrenergic agonist to relax bronchial smooth muscle and improve airflow. It is used to treat bronchospasm in patients with reversible obstructive airway disease, including asthma. The drug has rapid onset (within 5 minutes) and preferential beta-2 selectivity, producing bronchodilation with minimal cardiovascular effects.
Product is in late-stage lifecycle with moderate competitive pressure (score: 30/100), signaling potential team restructuring or consolidation as patent exclusivity erodes.
CLINICAL PHARMACOLOGY The prime action of beta-adrenergic drugs is to stimulate adenyl cyclase, the enzyme which catalyzes the formation of cyclic-3',5'-adenosine monophosphate (cyclic AMP) from adenosine triphosphate (ATP). The cyclic AMP thus formed mediates the cellular responses. In vitro…
Worked on ACCUNEB at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old
A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma
BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moACCUNEB roles emphasize mature-market execution: brand protection, generic defense, contract/formulary management, and physician relationship maintenance in primary care and pulmonology. Career longevity on this product is limited due to LOE trajectory; professionals should use this assignment to build expertise in respiratory markets and transition planning.